Eftilagimod alpha

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Retrieved on: 
Wednesday, April 7, 2021
Medical specialties, Medicine, Clinical medicine, Immunology, Monoclonal antibodies, Immutep, Biotechnology, Ieramilimab, Novartis, Antibody, Monoclonal antibody therapy, Eftilagimod alpha

The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.

Key Points: 
  • The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.
  • In particular, the claims of the patent are directed to compositions comprising LAG525 and spartalizumab, an anti-PD-1 antibody molecule, and related methods of use of the combination in the treatment of cancer.
  • The patent is co-owned by Novartis AG and Immutep S.A.S.
  • IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.)

IMMUTEP SECURES SECOND UNITED STATES PATENT GRANT FOR EFTILAGIMOD ALPHA IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR

Retrieved on: 
Tuesday, March 9, 2021
Patent law, Immutep, Eftilagimod alpha, Patent application, Divisional patent application, Term of patent, United States patent law

This United States patent was filed as a divisional application and follows the grant of the United States parent patent announced on 30 December 2020.

Key Points: 
  • This United States patent was filed as a divisional application and follows the grant of the United States parent patent announced on 30 December 2020.
  • The claims of this new patent build on the protection provided by the parent patent, and are directed to methods of treating cancer by administering Immuteps lead active immunotherapy candidate eftilagimod alpha (efti or IMP321) and a PD-1 pathway inhibitor.
  • The expiry date of the patent is 20 January 2036 (including a patent term adjustment of 12 days).
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep Expands Part B of TACTI-002 Study

Retrieved on: 
Friday, March 5, 2021
Cancer treatments, Clinical medicine, Drugs, Breakthrough therapy, Orphan drugs, Lung cancer, Cancer immunotherapy, Antineoplastic drugs, Pembrolizumab, Immutep, Non-small-cell lung carcinoma, Eftilagimod alpha

Immutep has commenced recruitment of an additional 13 second line Non-Small Cell Lung Cancer (NSCLC) patients, forming Stage 2 of Part B.

Key Points: 
  • Immutep has commenced recruitment of an additional 13 second line Non-Small Cell Lung Cancer (NSCLC) patients, forming Stage 2 of Part B.
  • The trial is a Phase II, Simons two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in up to 12 study centres across Australia, Europe, the UK and US.
  • Patients participating in three parts:
    Part B - Second line NSCLC, PD-X refractory
    TACTI-002 is an all-comer study in terms of PD-L1 status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology

Retrieved on: 
Thursday, January 28, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Immune system, Cancer immunotherapy, Clusters of differentiation, Immunotherapy, T cell, Eftilagimod alpha

Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their therapeutic vaccine clinical trials, and provide technical and clinical support to NEUVOGEN's development teams.

Key Points: 
  • Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their therapeutic vaccine clinical trials, and provide technical and clinical support to NEUVOGEN's development teams.
  • The company's goal is to enable widespread use and adoption of 89Zr CD8 Immuno-PET technology.
  • CD8 T cells play a pivotal role in cancer immunotherapy and our clinical studies have shown our 89Zr CD8 Immuno-PET imaging agent tracks and quantifies CD8 T cells in patients.
  • ImaginAb is advancing a pipeline of minibodies against oncology and immunology targets including the 89Zr CD8 ImmunoPET targeting CD8 T cells.

ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology

Retrieved on: 
Thursday, January 28, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Immune system, Cancer immunotherapy, Clusters of differentiation, Immunotherapy, T cell, Eftilagimod alpha

Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their therapeutic vaccine clinical trials, and provide technical and clinical support to NEUVOGEN's development teams.

Key Points: 
  • Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their therapeutic vaccine clinical trials, and provide technical and clinical support to NEUVOGEN's development teams.
  • The company's goal is to enable widespread use and adoption of 89Zr CD8 Immuno-PET technology.
  • CD8 T cells play a pivotal role in cancer immunotherapy and our clinical studies have shown our 89Zr CD8 Immuno-PET imaging agent tracks and quantifies CD8 T cells in patients.
  • ImaginAb is advancing a pipeline of minibodies against oncology and immunology targets including the 89Zr CD8 ImmunoPET targeting CD8 T cells.

Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study

Retrieved on: 
Thursday, January 7, 2021
Cancer treatments, Clinical medicine, Medicine, Lung cancer, Health effects of tobacco, Antineoplastic drugs, Cancer immunotherapy, Breakthrough therapy, Pembrolizumab, Non-small-cell lung carcinoma, Eftilagimod alpha, Immutep

Immutep reported encouraging interim data from TACTI-002 at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting on 10 November 2020.

Key Points: 
  • Immutep reported encouraging interim data from TACTI-002 at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting on 10 November 2020.
  • The data from 2nd line HNSCC patients was very robust and forms an excellent basis for additional clinical development in this indication.
  • In total 40 of 110 patients with 1st line NSCLC have now been recruited in Part A of TACTI-002.
  • The study is evaluating the combination of efti with MSDs KEYTRUDA (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

Retrieved on: 
Tuesday, December 29, 2020
Biotechnology, Eftilagimod alpha, Immutep, Patent, Transitional phrase, Biology, Medicine

This United States patent follows the grant of the corresponding European patent announced in November 2018.

Key Points: 
  • This United States patent follows the grant of the corresponding European patent announced in November 2018.
  • The claims of the patent protect Immuteps intellectual property relating to combined preparations comprising its lead active immunotherapy candidate eftilagimod alpha (efti or IMP321) and a PD-1 pathway inhibitor.
  • We are very pleased that this United States patent has been granted covering our lead product candidate, efti, in combination with key anti-PD-1 therapies.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Ultimovacs ASA Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab

Retrieved on: 
Tuesday, December 22, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Cancer treatments, Clinical medicine, Health sciences, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Cancer immunotherapy, Pembrolizumab, Head and neck cancer, Clinical trial, DAHANCA, Eftilagimod alpha

Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the initiation of FOCUS, a Phase II randomized clinical trial that will evaluate the Companys proprietary universal cancer vaccine, UV1, in 75 patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab.

Key Points: 
  • Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the initiation of FOCUS, a Phase II randomized clinical trial that will evaluate the Companys proprietary universal cancer vaccine, UV1, in 75 patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab.
  • The FOCUS trial is Ultimovacs fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020.
  • The FOCUS (First-line metastatic Or recurrent HNSCC/Checkpoint inhibitor UV1 Study) Phase II trial is an investigator-sponsored, randomized Phase II clinical trial that will recruit patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma across 10 clinical sites in Germany.
  • The fourth trial, FOCUS, is an investigator-sponsored, randomized clinical trial, enrolling 75 patients with metastatic head and neck cancer receiving pembrolizumab as standard of care, to evaluate the impact of adding UV1 to this regimen.

Immutep Upscales Efti Manufacturing

Retrieved on: 
Wednesday, December 16, 2020
Life sciences, Biotechnology, Articles, Immutep, WuXi Biologics, Biopharmaceutical, Single-use bioreactor, Bioreactor, Mashan, Eftilagimod alpha

This follows the very encouraging interim results Immutep announced from its efti clinical trials at SITC (10 November 2020) and SABS (10 December 2020) and will be funded by the recent conversion of warrants on Immutep.

Key Points: 
  • This follows the very encouraging interim results Immutep announced from its efti clinical trials at SITC (10 November 2020) and SABS (10 December 2020) and will be funded by the recent conversion of warrants on Immutep.
  • Immutep is planning to increase the efti manufacturing process from 200L to 2,000L capacity bioreactors at the WuXi Biologics manufacturing plant (Mashan site, Wuxi, China), with the major scale up steps taking place throughout 2021.
  • Chris Chen, CEO of WuXi Biologics said: We are very pleased to be moving the scale up process forward for efti with Immutep.
  • Marc Voigt, CEO of Immutep said: Following the very encouraging interim Overall Survival data announced last week from our largest clinical trial, AIPAC, we have activated our plans to upscale the manufacturing of efti to 2,000L single-use bioreactors to prepare for potential commercial manufacturing and potential registration trials in multiple indications.

Immutep Operational Update

Retrieved on: 
Tuesday, December 15, 2020
Immutep, Immunotherapy, Medicine, Health care, Eftilagimod alpha

Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022

Key Points: 
  • Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022
    Sydney, AUSTRALIA, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on efti clinical programs.
  • Immutep continues to prepare for a new randomised, controlled Phase II clinical study in approximately 160 1st line HNSCC patients.
  • Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.